mepenzolate (Discontinued)

Brand and Other Names:Cantil
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

tablet

  • 25mg

Peptic Ulcer

25-50 mg PO q6hr (with meals & HS), titrate as needed

Elderly: Start at lower end of dose

Safety & efficacy not established

Peptic ulcer

25-50 mg PO q6hr (with meals & HS), titrate as needed

Elderly: Start at lower end of dose

Next:

Interactions

Interaction Checker

and mepenzolate

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            Frequency Not Defined

            Dizziness

            Confusion

            Headache

            Insomnia

            Nervousness

            Weakness

            Drowsiness

            Tachycardia

            Palpitations

            Vomiting

            Nausea

            Taste loss

            Dry mouth

            Constipation

            Bloated feeling

            Urinary retention

            Urinary hesitancy

            Increased IOP

            Cycloplegia

            Mydriasis

            Blurred vision

            Anaphylaxis

            Urticaria

            Decreased sweating

            Inhibition of lactation

            Impotence

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity to mepenzolate or related compounds

            Closed-angle glaucoma, myasthenia gravis, hemorrhage with cardiovascular instability, paralytic ileus, intestinal atony of elderly/debilitated patient, obstructive uropathy, toxic megacolon, GI obstruction, tachycardia secondary to cardiac insufficiency or thyrotoxicosis

            Cautions

            Renal/hepatic impairment, BPH, CHF, CAD, HTN, COPD, hiatal hernia, reflux esophagitis, mitral stenosis, brain damage or spastic paralysis in children, salivary secretion disorder, Down syndrome, autonomic neuropathy, hyperthyroidism, tachyarrythmia, toxin-mediated diarrhea

            Elderly (see Beers Criteria)

            Risk of heat prostration in high environmental temperature

            May affect alertness/ability to perform hazardous tasks

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: B

            Lactation: unlikely to be excreted in breast milk

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Postganglionic parasympathetic inhibitor. Inhibits gastric acid and pepsin secretion and inhibits spontaneous contractions of the colon

            Pharmacokinetics

            Absorption: Limited

            Excretion: Urine (3-33%) & feces

            Previous
            Next:

            Images

            Previous
            Next:
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.